Electronic Warning System for Atrial Fibrillation

Electronic Warning System to Improve Stroke Prevention in Atrial Fibrillation - A Quality Improvement Initiative at the University Hospital Bern

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02455102

Enrollment

1707

Registered

2015-05-27

Start date

2014-09-30

Completion date

2015-10-31

Last updated

2015-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Prevention, Anticoagulation, Electronic warning system

Brief summary

The aim of this randomized controlled study is to evaluate whether a newly designed electronic warning system will increase the initiation rate of adequate stroke preventive measures in patients with atrial fibrillation.

Detailed description

A large proportion of patients with atrial fibrillation do not receive stroke prevention therapy in line with the guidelines, in spite of the presence of an increased risk of stroke. It will be investigated whether an electronic alert to physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will increase the rate of adequate stroke preventive measures as compared to a control group of patients without an electronic alert. The electronic alerts will be sent if patients with atrial fibrillation but without adequate stroke preventive measures receive in-patient treatment at the University Hospital Bern. The electronic alert system includes a feature that helps the physicians in charge to evaluate the CHA2DS2VASC Score. At the end of the hospital stay medical discharge letters will be reviewed for initiation of adequate stroke preventive measures.

Interventions

OTHERElectronic warning alert

A newly-installed warning system for stroke prevention in atrial fibrillation.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All in-patients with atrial fibrillation

Exclusion criteria

* Ongoing anticoagulant therapy

Design outcomes

Primary

Measure	Time frame	Description
Rate of initiation of adequate measures to prevent stroke (oral anticoagulant prescription) by physician in charge	End of hospital stay (expected average duration of 1 week)	Reviewed from discharge letter

Secondary

Measure	Time frame
Use of the CHA2DS2VASc score calculation tool by the physician in charge	During hospital stay (expected average duration of 1 week)
Rate of correct evaluation of the CHA2DS2VASC Score through the calculation tool by physician in charge	End of hospital stay (expected average duration of 1 week)

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026